2,017 results on '"Hayman, Suzanne R."'
Search Results
2. Mode of progression in smoldering multiple myeloma: a study of 406 patients
3. Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma – updated results after 18-year follow-up
4. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
5. Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis
6. Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100
7. Muscle and fat composition in patients with newly diagnosed multiple myeloma
8. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
9. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
10. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
11. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
12. Conditional survival in multiple myeloma and impact of prognostic factors over time
13. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
14. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas
15. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
16. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
17. Outcomes after biochemical or clinical progression in patients with multiple myeloma
18. Metformin and cytokine release syndrome after immune effector cell therapy.
19. First relapse in patients with multiple myeloma: Outcomes and predictors.
20. Class comparison of BCMA-directed therapies in relapsed multiple myeloma.
21. Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.
22. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
23. Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy
24. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma
25. Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis
26. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma
27. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States
28. Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
29. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
30. Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis
31. Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma
32. Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100
33. Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
34. Prognostic restaging after treatment initiation in patients with AL amyloidosis
35. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
36. Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients
37. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
38. Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)
39. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities
40. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation
41. Utility of serum free light chain ratio in response definition in patients with multiple myeloma
42. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy
43. Outpatient Management of CAR-T and Teclistamab for Patients with Lymphoma and Multiple Myeloma
44. Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation
45. A simple additive staging system for newly diagnosed multiple myeloma
46. Revisiting complete response in light chain amyloidosis
47. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis
48. The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma
49. Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
50. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.